Header Logo

Connection

MOHIT KHERA to Testosterone

Back to Details
This is a "connection" page, showing publications MOHIT KHERA has written about Testosterone.
MOHIT KHERA
Connection Strength
16.307
Testosterone
  1. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025 Oct 04; 13(4):548-573.
    View in: PubMed
    Score: 0.634
  2. Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. J Sex Med. 2025 Sep 04; 22(9):1564-1571.
    View in: PubMed
    Score: 0.630
  3. Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care. Sex Med Rev. 2025 Jul 03; 13(3):373-380.
    View in: PubMed
    Score: 0.623
  4. Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025 04 08; 22(3):432-438.
    View in: PubMed
    Score: 0.613
  5. Newer formulations of oral testosterone undecanoate: development and liver side effects. Sex Med Rev. 2025 Jan 31; 13(1):33-40.
    View in: PubMed
    Score: 0.605
  6. Hypogonadism management and cardiovascular health. Postgrad Med. 2020 Dec; 132(sup4):35-41.
    View in: PubMed
    Score: 0.450
  7. Controversies with testosterone therapy. Can J Urol. 2020 08; 27(S3):20-23.
    View in: PubMed
    Score: 0.443
  8. Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male. Eur Urol Focus. 2018 04; 4(3):321-323.
    View in: PubMed
    Score: 0.387
  9. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep. 2018 Jun 30; 19(8):67.
    View in: PubMed
    Score: 0.383
  10. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med. 2018 02; 15(2):148-158.
    View in: PubMed
    Score: 0.372
  11. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. Med Clin North Am. 2018 Mar; 102(2):361-372.
    View in: PubMed
    Score: 0.368
  12. Alternatives to Testosterone Therapy: A Review. Sex Med Rev. 2018 01; 6(1):106-113.
    View in: PubMed
    Score: 0.368
  13. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017 Nov; 27(6):511-515.
    View in: PubMed
    Score: 0.366
  14. Testosterone inhibits the growth of prostate cancer xenografts in nude mice. BMC Cancer. 2017 Sep 07; 17(1):635.
    View in: PubMed
    Score: 0.362
  15. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM?2015). J Sex Med. 2016 12; 13(12):1787-1804.
    View in: PubMed
    Score: 0.344
  16. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016 07; 91(7):908-26.
    View in: PubMed
    Score: 0.333
  17. Testosterone Therapies. Urol Clin North Am. 2016 May; 43(2):185-93.
    View in: PubMed
    Score: 0.327
  18. Male hormones and men's quality of life. Curr Opin Urol. 2016 Mar; 26(2):152-7.
    View in: PubMed
    Score: 0.326
  19. Testosterone is Protective against Cardiac Disease: Pro. J Urol. 2016 04; 195(4 Pt 1):831-2.
    View in: PubMed
    Score: 0.324
  20. Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer. Asian J Androl. 2015 Sep-Oct; 17(5):807-10.
    View in: PubMed
    Score: 0.315
  21. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015 Nov; 194(5):1271-6.
    View in: PubMed
    Score: 0.309
  22. Controversies in testosterone supplementation therapy. Asian J Androl. 2015 Mar-Apr; 17(2):175-6.
    View in: PubMed
    Score: 0.304
  23. RE: Testosterone treatment is a potent tumor promoter for the rat prostate. Endocrinology. 2015 Jan; 156(1):L1-2.
    View in: PubMed
    Score: 0.301
  24. Reply to Julia Klap and Kevin R. Loughlin's letter to the editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23. Eur Urol. 2014 Aug; 66(2):e33.
    View in: PubMed
    Score: 0.287
  25. Controversies in the treatment of male hypogonadism. Urology. 2014 Apr; 83(4):957.
    View in: PubMed
    Score: 0.285
  26. Patients with testosterone deficit syndrome and depression. Arch Esp Urol. 2013 Sep; 66(7):729-36.
    View in: PubMed
    Score: 0.274
  27. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan; 65(1):115-23.
    View in: PubMed
    Score: 0.273
  28. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013 Mar; 125(2):8-18.
    View in: PubMed
    Score: 0.265
  29. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug; 190(2):639-44.
    View in: PubMed
    Score: 0.264
  30. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med. 2013 Feb; 10(2):562-9.
    View in: PubMed
    Score: 0.257
  31. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl. 2012 Sep-Oct; 33(5):927-37.
    View in: PubMed
    Score: 0.247
  32. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012 Mar; 15(1):14-21.
    View in: PubMed
    Score: 0.242
  33. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome. J Androl. 2012 Jul-Aug; 33(4):570-3.
    View in: PubMed
    Score: 0.240
  34. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011 Nov; 8(11):3204-13.
    View in: PubMed
    Score: 0.238
  35. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011 Sep; 186(3):1005-11.
    View in: PubMed
    Score: 0.237
  36. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011 Apr; 185(4):1256-60.
    View in: PubMed
    Score: 0.230
  37. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr; 6(4):1165-1170.
    View in: PubMed
    Score: 0.199
  38. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 Mar; 6 Suppl 3:234-8.
    View in: PubMed
    Score: 0.199
  39. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007 Nov; 34(4):549-53, vi.
    View in: PubMed
    Score: 0.183
  40. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025 May; 13(4):882-893.
    View in: PubMed
    Score: 0.147
  41. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
    View in: PubMed
    Score: 0.139
  42. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 07 13; 389(2):107-117.
    View in: PubMed
    Score: 0.135
  43. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res. 2022 Nov; 34(7):685-690.
    View in: PubMed
    Score: 0.122
  44. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100?mg IM weekly or 200?mg IM biweekly. Int J Impot Res. 2022 Sep; 34(6):558-563.
    View in: PubMed
    Score: 0.118
  45. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):630-637.
    View in: PubMed
    Score: 0.118
  46. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men. Cancer Prev Res (Phila). 2021 07; 14(7):719-728.
    View in: PubMed
    Score: 0.116
  47. Testosterone's Role in COVID-19. J Sex Med. 2021 05; 18(5):843-848.
    View in: PubMed
    Score: 0.116
  48. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. J Sex Med. 2021 01; 18(1):83-98.
    View in: PubMed
    Score: 0.114
  49. Controversies in Testosterone Therapy. Sex Med Rev. 2021 01; 9(1):149-159.
    View in: PubMed
    Score: 0.113
  50. A Critique of the AUA Guidelines on Testosterone Deficiency. J Sex Med. 2020 04; 17(4):561-564.
    View in: PubMed
    Score: 0.106
  51. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. Clin Endocrinol (Oxf). 2019 12; 91(6):885-891.
    View in: PubMed
    Score: 0.105
  52. Caffeine intake is not associated with serum testosterone levels in adult men: cross-sectional findings from the NHANES 1999-2004 and 2011-2012. Aging Male. 2019 Mar; 22(1):45-54.
    View in: PubMed
    Score: 0.095
  53. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clin Endocrinol (Oxf). 2018 07; 89(1):3-10.
    View in: PubMed
    Score: 0.094
  54. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population. J Sex Med. 2017 01; 14(1):88-97.
    View in: PubMed
    Score: 0.086
  55. Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction. J Sex Med. 2016 08; 13(8):1183-98.
    View in: PubMed
    Score: 0.084
  56. The nanochannel delivery system for constant testosterone replacement therapy. J Sex Med. 2015 Jun; 12(6):1375-80.
    View in: PubMed
    Score: 0.077
  57. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015 Feb; 90(2):224-51.
    View in: PubMed
    Score: 0.076
  58. Delivering enhanced testosterone replacement therapy through nanochannels. Adv Healthc Mater. 2015 Feb 18; 4(3):446-51.
    View in: PubMed
    Score: 0.074
  59. The safety of testosterone supplementation therapy in prostate cancer. Nat Rev Urol. 2014 Sep; 11(9):526-30.
    View in: PubMed
    Score: 0.073
  60. Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014 Jul; 11(7):1636-45.
    View in: PubMed
    Score: 0.072
  61. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry. Postgrad Med. 2013 Mar; 125(2):19-29.
    View in: PubMed
    Score: 0.066
  62. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012; 7:321-30.
    View in: PubMed
    Score: 0.064
  63. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012 May; 13(5):688-98.
    View in: PubMed
    Score: 0.062
  64. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(?)) insertion. J Sex Med. 2012 Feb; 9(2):594-601.
    View in: PubMed
    Score: 0.061
  65. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011 May; 123(3):17-27.
    View in: PubMed
    Score: 0.058
  66. Androgen replacement therapy after prostate cancer treatment. Curr Urol Rep. 2010 Nov; 11(6):393-9.
    View in: PubMed
    Score: 0.056
  67. Exploring the link between muscle quality and erectile dysfunction: assessing the impact of mass and strength. Sex Med Rev. 2025 Oct 04; 13(4):643-651.
    View in: PubMed
    Score: 0.040
  68. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
    View in: PubMed
    Score: 0.035
  69. Oral testosterone therapy: past, present, and future. Sex Med Rev. 2023 04 03; 11(2):124-138.
    View in: PubMed
    Score: 0.033
  70. Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015. Cancer Epidemiol. 2022 08; 79:102172.
    View in: PubMed
    Score: 0.031
  71. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022 05; 10(4):669-676.
    View in: PubMed
    Score: 0.031
  72. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
    View in: PubMed
    Score: 0.030
  73. The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. Cancer Causes Control. 2021 Sep; 32(9):965-976.
    View in: PubMed
    Score: 0.029
  74. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature. Sex Med Rev. 2021 07; 9(3):393-405.
    View in: PubMed
    Score: 0.029
  75. Is treatment of hypogonadism safe for men after a solid organ transplant? Results from a retrospective controlled cohort study. Int J Impot Res. 2022 Jan; 34(1):50-54.
    View in: PubMed
    Score: 0.028
  76. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019 May 30; 5(1):38.
    View in: PubMed
    Score: 0.026
  77. Diagnosing secondary hypogonadism: important consequences for fertility and reversibility. BJU Int. 2016 Apr; 117(4):552-4.
    View in: PubMed
    Score: 0.020
  78. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med. 2014 Nov; 11(11):2764-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.